Shengnuo Biology announced that it is expected to achieve a net income attributable to the owners of the parent company of 50.0717 million yuan to 61.1987 million yuan in the first three quarters of 2024, an increase of 43.90% to 75.88% year-on-year; It is expected to achieve a net income attributable to the owners of the parent company after deducting non-recurring gains and losses of 47.6484 million yuan to 58.237 million yuan, an increase of 103.93% to 149.25% year-on-year. During the reporting period, the company's sales revenue of polypeptide active pharmaceutical ingredients and formulations business saw significant year-on-year growth, resulting in a significant year-on-year growth in the company's performance.
圣诺生物：预计前三季度净利润同比增加43.90%至75.88%
Shengnuo Biotechnology: It is expected that the net income in the first three quarters will increase by 43.90% to 75.88% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated